Roundtable Healthcare Adds Kahlon to Operating Team

Roundtable Healthcare Partners appointed Amardeep Kahlon as operating partner this week, adding pharmaceutical industry expertise to its value-creation team as the firm scales its portfolio across specialty healthcare services. Kahlon spent over two decades building commercial operations at companies spanning specialty pharma, rare disease treatments, and pharmaceutical distribution — exactly the sectors where Roundtable has been most active since its 2020 launch.

The hire comes as healthcare-focused private equity firms increasingly compete on operational support rather than just capital. Roundtable, which manages roughly $850 million across two funds, has built a reputation for hands-on portfolio company development in niches like specialty distribution, lab services, and physician practice management. Adding someone who's launched drugs and scaled distribution networks isn't window dressing — it's table stakes in a market where every middle-market healthcare deal gets twenty bids.

Kahlon's most recent role was Chief Commercial Officer at Amneal Pharmaceuticals, where he oversaw a 1,000-person commercial organization covering both specialty and generics divisions. Before that, he built the U.S. commercial launch strategy for Sobi's rare disease portfolio and led sales operations at Hikma Pharmaceuticals. It's the kind of résumé that signals experience turning clinical assets into revenue engines — a skill that translates directly to healthcare services businesses trying to scale payor relationships or expand into adjacent specialties.

The firm didn't disclose compensation or equity terms, but operating partner roles at healthcare-focused PE shops typically include both cash comp and carry participation tied to portfolio performance. Kahlon will split time between Roundtable's Lake Forest, Illinois headquarters and portfolio company sites, according to a company statement.

The operating partner model has evolved from a post-retirement gig for former executives into a core competitive advantage for PE firms. In healthcare specifically, where regulatory complexity and payor dynamics create unique post-acquisition challenges, firms with deep operating benches can credibly promise portfolio companies more than money.

Roundtable's existing operating team includes veterans from Cardinal Health, AmerisourceBergen, and CVS Health — all players in the pharmaceutical supply chain. Kahlon adds a commercial and launch-focused dimension that complements the firm's supply chain and operations expertise. That matters when you're backing companies trying to navigate specialty drug distribution, prior authorization workflows, or direct-to-patient fulfillment models.

The firm's portfolio strategy centers on fragmented healthcare services subsectors ripe for consolidation. Recent holdings include specialty pharmacy networks, diagnostic lab platforms, and physician practice groups in high-acuity specialties. These aren't software plays or tech-enabled services — they're traditional healthcare businesses where operational improvement drives returns more than financial engineering.

That's where someone like Kahlon becomes valuable. Scaling a specialty pharmacy from regional to national coverage requires payor contracting expertise, regulatory navigation, and commercial strategy — not just capital. The same goes for building a physician network that can command better payor rates through scale and quality metrics. You need operators who've done it, not consultants who've studied it.

Kahlon's career spans the full spectrum of pharmaceutical commercialization. At Sobi, a Swedish biopharma focused on rare diseases, he led U.S. market entry for therapies treating hemophilia and genetic metabolic disorders. Rare disease launches demand deep payor negotiation skills and patient access program design — capabilities that translate well to specialty healthcare services where similar hub-and-spoke fulfillment models dominate.

At Amneal, he managed a bifurcated commercial model: high-touch specialty sales for branded products and high-volume generic distribution through wholesalers and retail chains. Running both simultaneously requires balancing completely different sales motions, channel strategies, and margin profiles. That dual-model experience maps cleanly to Roundtable's portfolio mix, where some companies operate high-margin specialty services and others run volume-driven distribution businesses.

His earlier stint at Hikma Pharmaceuticals, a generics and injectables manufacturer, focused on scaling hospital and retail distribution across competitive therapeutic categories. Managing channel conflict, formulary positioning, and contracting in commoditized categories builds a different muscle than rare disease launches — one that's equally relevant when optimizing a portfolio company's payor mix or geographic footprint.

None of this is breakthrough innovation. It's blocking and tackling — the work of building distribution networks, negotiating contracts, and hitting revenue targets in regulated markets. That's exactly what makes it valuable in a PE context, where the job isn't inventing new business models but executing proven ones faster and at greater scale.

The operating partner title covers a wide range of actual work, depending on the firm and the portfolio. At some shops, it's a part-time advisory role with minimal hands-on engagement. At others, operating partners function as interim C-suite executives, spending weeks or months embedded in portfolio companies during critical transitions like post-acquisition integration, leadership changes, or major strategic pivots.

Roundtable Healthcare Partners launched in 2020 with $300 million in committed capital, targeting lower-middle-market healthcare services businesses with enterprise values between $25 million and $150 million. The firm's strategy focuses on subsectors where independent operators still dominate but where consolidation tailwinds are accelerating due to regulatory changes, payor pressure, or technology adoption.

The firm closed its second fund in 2023, bringing total assets under management to roughly $850 million. That puts it in the middle of the pack among healthcare-focused PE firms — big enough to lead platform acquisitions and execute add-on strategies, but not so large that it's competing with the multi-billion-dollar mega-funds for assets.

Portfolio companies typically fit one of three archetypes: specialty distribution networks serving high-touch patient populations, diagnostic or lab service providers benefiting from testing volume growth, or physician practice platforms in procedural specialties with favorable reimbursement trends. The common thread is predictable revenue tied to clinical necessity rather than discretionary demand.

That's a deliberate choice. Healthcare services businesses tied to chronic disease management, specialty drug fulfillment, or high-acuity diagnostics generate durable cash flows even during economic downturns. Patients don't stop taking biologics or getting cancer screenings when GDP contracts. That recession-resistance matters to both the firm and its limited partners, who view healthcare as a defensive allocation.

The value-creation playbook is classic buy-and-build: acquire a regional platform, bolt on 3-5 smaller competitors or adjacent service lines, professionalize operations and back-office functions, and exit to a strategic acquirer or larger PE firm within 4-6 years. Kahlon's role will likely center on the middle phase — the operational professionalization and commercial expansion that makes a collection of bolt-ons function as a unified platform.

Financial buyers win deals by promising better growth and higher exit multiples than the status quo. Delivering on that promise requires solving boring operational problems: integrating IT systems across acquisitions, harmonizing billing practices, standardizing clinical protocols, and consolidating payor contracts to capture volume discounts.

Kahlon's commercial background suggests he'll focus on revenue-side value creation — expanding into new geographies, negotiating better reimbursement terms, launching new service lines adjacent to existing capabilities, or building direct-to-patient channels that bypass traditional intermediaries. These initiatives require healthcare industry fluency that most PE investment professionals don't have, no matter how many healthcare deals they've closed.

The healthcare services sector has attracted record private equity investment over the past five years, with deal volume peaking in 2021 before moderating in 2023-2024 as interest rates rose and exit markets tightened. Physician practice roll-ups, specialty pharmacies, and diagnostic platforms have been particularly active acquisition targets.

But the playbook that worked from 2015-2022 faces new challenges. Regulatory scrutiny of PE-backed healthcare providers has intensified, with the FTC blocking several physician practice mergers and Congress proposing transparency requirements for private equity ownership in healthcare. Reimbursement pressure from commercial payors and Medicare Advantage plans is compressing margins in previously attractive subsectors.

Add-on acquisition multiples have also inflated as competition for targets has increased. What used to be a 5x EBITDA bolt-on now trades at 7-8x, eroding the multiple arbitrage that made buy-and-build strategies so lucrative. Firms need to drive more organic growth and operational improvement to hit return targets — which is exactly why operating partners with real industry experience have become more valuable.

Exit markets have cooled as well. Strategic buyers remain active but more selective, and the IPO window for healthcare services companies has been effectively closed since late 2021. Sponsor-to-sponsor deals still happen, but secondary buyers demand clear evidence of operational transformation and growth acceleration, not just financial engineering.

Private equity's expansion into healthcare has drawn bipartisan political attention. Senator Elizabeth Warren and others have called for stricter oversight of PE ownership in healthcare, citing concerns about patient care quality, surprise billing practices, and staffing cuts at acquired facilities. The FTC under Lina Khan has taken a more aggressive stance on healthcare consolidation, challenging deals that historically would have sailed through antitrust review.

For firms like Roundtable operating in specialty niches rather than primary care or hospitals, regulatory risk is lower but not zero. Specialty pharmacy consolidation, for instance, has attracted scrutiny from state regulators and payor groups concerned about pricing power and patient steering. Any portfolio strategy dependent on building regional or national scale needs to account for the possibility that future transactions face regulatory hurdles.

Operating partner appointments don't generate press releases because they're vanity hires. They happen when a firm identifies specific value-creation gaps in its portfolio and brings in expertise to close them. For Roundtable, the Kahlon hire signals an intention to drive more aggressive commercial growth across portfolio companies — expanding payor networks, launching adjacent service lines, or building patient access capabilities that create competitive moats.

Success won't be measured by advisory board meetings attended or white papers published. It'll show up in portfolio company EBITDA growth, payor contract wins, and the revenue multiples Roundtable achieves at exit. If the firm's next fund closes at $1 billion-plus and its current portfolio exits at 3x+ net multiples, Kahlon's contribution will have been real. If returns underperform and portfolio companies struggle to scale, the operating partner model will have been expensive overhead.

The healthcare services PE game has shifted from easy wins to hard work. Multiples are high, exits are harder, and regulatory risk is real. Firms that win over the next cycle will be the ones that can genuinely improve portfolio company operations, not just consolidate them. Hiring someone who's actually launched products and built sales organizations is a bet that operational expertise still matters more than financial engineering.

Whether that bet pays off depends on execution — the part that happens after the press release.

The operating partner model emerged in the 1990s as PE firms sought to differentiate beyond price in competitive auctions. Early adopters like KKR and Clayton, Dubilier & Rice built formal operating groups staffed by former CEOs and functional executives who could credibly promise operational transformation to sellers and management teams.

Healthcare-focused firms adopted the model more slowly, but it's now standard practice among top-tier players. Firms like Welsh Carson, Summit Partners, and Shore Capital Partners maintain deep operating benches with sector-specific expertise in areas like revenue cycle management, payor contracting, clinical operations, and regulatory compliance.

The model works best when operating partners have both functional expertise and healthcare domain knowledge. A former CFO who's never navigated Medicare reimbursement or managed a specialty pharmacy network won't add much value in due diligence or post-acquisition integration. Kahlon's combination of commercial leadership and pharmaceutical industry experience gives Roundtable credibility in exactly the subsectors where it invests most actively.

The risk is that operating partners become expensive overhead if they're not tightly integrated into deal execution and portfolio management. The best firms treat operating partners as core investment team members who participate in diligence, sit on portfolio company boards, and have compensation tied directly to portfolio performance. The worst treat them as advisors who show up for quarterly board meetings and offer generic advice.

The Kahlon appointment suggests Roundtable is gearing up for a more aggressive growth phase across its portfolio. Operating partner hires typically precede either a wave of new platform investments or a push to scale existing portfolio companies ahead of exit processes. With Fund II still in its investment period, both are plausible.

Key indicators to track over the next 12-18 months:

New platform acquisitions in specialty pharmacy, diagnostics, or physician practice management — subsectors where Kahlon's commercial expertise is most directly applicable. If Roundtable announces a specialty pharmacy or rare disease service platform investment within the next quarter, it'll signal that Kahlon was brought in with a specific deal thesis in mind.

Add-on acquisition velocity across existing portfolio companies. Accelerated M&A activity would indicate the firm is building scale ahead of exit processes, likely targeting transactions in the 12-24 month window.

Portfolio company commercial announcements — new payor contracts, geographic expansions, service line launches. These are the tangible outputs of effective operating partner engagement and would validate the value-creation thesis.

Exit activity in Fund I portfolio companies. If Roundtable begins marketing mature assets within the next 6-12 months, it'll need to demonstrate operational improvements that justify premium exit multiples. Kahlon's work will be part of that story.